Farringdon Capital’s GSK GSK Stock Holding History

Farringdon Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.13M	Buy	78,744 +8,830	+13%	+$467K	2.05%	13
2026 Q1	$3.86M	Buy	69,914 +23,608	+51%	+$1.28M	0.85%	22
2025 Q4	$2.27M	Buy	+46,306	New	+$2.16M	0.56%	44
2025 Q3	–	Sell	-9,610	Closed	-$369K	–	537
2025 Q2	$369K	Buy	+9,610	New	+$367K	0.12%	277

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Farringdon Capital's GSK Position: Q2 2026 in Review

Farringdon Capital increased its GSK (GSK) stake by 13% in Q2 2026, buying an estimated $467K and bringing the position to 78,744 shares worth $4.13M. The position accounts for 2.05% of the portfolio, ranked #13.

Farringdon Capital first reported a position in GSK in Q2 2025 and has held it in 4 quarters since. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Farringdon Capital held 78,744 shares of GSK worth $4.13M as of Q2 2026.
Farringdon Capital bought 8,830 GSK shares in Q2 2026, an estimated $467K.
GSK made up 2.05% of Farringdon Capital's portfolio in Q2 2026, its #13 holding.
Farringdon Capital first reported a position in GSK in Q2 2025 and has held it in 4 quarters since.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Farringdon Capital's 13F filing for Q2 2026, filed 12 Aug 2026.